Ezetimibe, a cholesterol absorption inhibitor that targets uptake at the jejunal enterocyte brush border, can be used alternatively or in combination with statins, while PCSK9 inhibitors such as Evolocumab and Alirocumab, are indicated in familiar hypercholesterolemia (Table 1). This evidence concerns the gene PCSK9 and familial hypercholesterolemia.